Testosterone therapy did not raise heart attack or stroke risk in the largest trial yet
The TRAVERSE trial gave 5,246 men with low testosterone and heart risk either testosterone gel or a placebo. Major cardiovascular events were no more common, but other risks appeared.
Testosterone prescriptions have risen sharply, alongside long-running concern that they might increase heart attacks and strokes. The US Food and Drug Administration asked manufacturers to run a large trial. TRAVERSE was the result.
A. Michael Lincoff of the Cleveland Clinic and colleagues published the results in the New England Journal of Medicine in 2023. The trial enrolled 5,246 men aged 45 to 80 with confirmed low testosterone and symptoms, who also had existing cardiovascular disease or a high risk of it. They applied either testosterone gel or a placebo gel daily.
What they found
- Major cardiovascular events (cardiovascular death, heart attack or stroke) occurred in 7.0 percent of the testosterone group and 7.3 percent of the placebo group. Testosterone met the trial's test for being no worse.
- Atrial fibrillation, acute kidney injury and pulmonary embolism were more common with testosterone.
What it means
For men with genuinely low testosterone and symptoms, treatment does not appear to raise the risk of heart attack or stroke. It is not risk-free, and the trial says nothing about men with normal levels using testosterone to build muscle or feel younger.
How to apply it
- Low testosterone should be confirmed with at least two morning blood tests, together with symptoms such as low libido or fatigue.
- Address reversible causes first: excess body fat, poor sleep, heavy drinking and some medications.
- If you start therapy, it needs monitoring: blood count, PSA and heart rhythm symptoms.
- Testosterone suppresses natural production and sperm. Men who want children need specific advice.
- Do not use testosterone without a prescription.
A note on the evidence
Many men stopped treatment during the trial, and it was designed to rule out harm rather than show benefit. It was funded by testosterone manufacturers. The findings apply to men with diagnosed low testosterone, not to performance use.
Sources
- Lincoff AM et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine, 2023. doi:10.1056/NEJMoa2215025




